Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis?
In primary malignant brain tumors increased vascularity and marked edema strongly suggest a possible role of the vascular endothelial growth factor/vascular permeability factor (VEGF/VPF). This was confirmed by earlier in situ hybridization studies, by analysis of the expression of the mitogen in different subsets of glioblastoma cells, and by the fact that the VEGF/VPF receptor flt-1 (fms-like tyrosine kinase) is up-regulated in tumor cells in vivo. To assess and quantify the expression of the VEGF/VPF gene and of the receptor gene, 26 surgical specimens of brain tumor tissue from 24 patients were analyzed. In most malignant gliomas, the expression level of the VEGF/VPF gene is elevated and can be increased up to 20- to 50-fold in comparison with low-grade tumors. Using polymerase chain reaction-based amplification, it could be shown that the messenger RNAs of three different VEGF/VPF forms are synthesized in tumor tissue samples. Northern blot studies revealed that in some samples a significant expression of the gene coding for placenta growth factor, a growth factor closely related to VEGF/VPF, was observed. In addition, using a radioreceptor assay it was possible to detect high VEGF/VPF-like activity in the cyst fluids of brain tumors, indicating the accumulation of the mitogen and permeability factor in brain tumor cysts. Further investigations revealed that astrocytoma and glioblastoma cells in culture express the VEGF/VPF gene and secrete the VEGF/VPF protein, whereas gene expression of the two known VEGF/VPF receptors, kinase insert domain-containing receptor and flt-1, could not be detected. These data support previous reports, which stated that VEGF/VPF acts as a paracrine growth and permeability factor in brain tumors and may contribute to tumor growth by initiating tumor angiogenesis.
Weindel
K
K
Institute of Molecular Medicine, Albert-Ludwigs-University, Freiburg, Germany.
Moringlane
J R
JR
Marmé
D
D
Weich
H A
HA
D000818:Animals; D001254:Astrocytoma / Q000098:blood supply / Q000235:genetics; D001812:Blood-Brain Barrier / Q000235:genetics / Q000502:physiology; D001932:Brain Neoplasms / Q000098:blood supply* / Q000235:genetics; D002417:Cattle; D002460:Cell Line; D002528:Cerebellar Neoplasms / Q000098:blood supply; D003560:Cysts / Q000235:genetics / Q000503:physiopathology; D016228:Endothelial Growth Factors / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D004730:Endothelium, Vascular / Q000503:physiopathology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D005909:Glioblastoma / Q000098:blood supply / Q000235:genetics; D006801:Humans; D008222:Lymphokines / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D008527:Medulloblastoma / Q000098:blood supply; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000503:physiopathology*; D009837:Oligodendroglioma / Q000098:blood supply; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors